Results 201 to 210 of about 142,066 (310)

Uncovering mirnomes of patients with interstitial lung diseases and an underlying autoimmune process. [PDF]

Respir Res
Sánchez-Pernaute O, Benítez Y, Vadillo Font C, Nieto MA, Cebrián L, López-Muñiz B, Romero-Bueno FI, Godoy H, Laporta R, Del Pozo Abeijón MV, Abásolo Alcázar L, Mínguez P, Rodríguez Nieto MJ.   +12 more
europepmc   +1 more source

Fine Particulate Matter Constituents, Ozone, and Systemic Lupus Erythematosus: A Large General‐Population Cohort Analysis With Extended Quantile g‐Computation

Arthritis &Rheumatology, EarlyView.
Objective The aim of this study was to investigate whether exposure to mixture of individual fine particulate matter (PM2.5) chemical constituents is associated with incident systemic lupus erythematosus (SLE) and if ozone modifies this association and/or is associated with SLE onset.
Naizhuo Zhao, Sasha Bernatsky, Sharon Dowell, Brittany Banbury, Jeffrey R. Curtis, Grace C. Wright, Emily E. Holladay, Amy Mudano, Cristiano S. Moura, Gail S. Kerr   +9 more
wiley   +1 more source

Is Immunotherapy a Contraindication for Treating Lung Cancer Patients with Interstitial Lung Diseases? A Review of the Literature. [PDF]

J Clin Med
Pagliaro R, Della Monica P, D'Agnano V, Schiattarella A, D'Orologio A, Medusa PM, Stella GM, Colapietra F, Perrotta F, Bianco A, Di Domenico M, Scialò F.   +11 more
europepmc   +1 more source

Integrated Clinical and Proteomic Profiling of CD19 CAR‐T Cell Therapy in Progressive Systemic Sclerosis

Arthritis &Rheumatology, Accepted Article.
Objective To characterize the clinical, immunologic, and proteomic changes associated with CD19 chimeric antigen receptor T‐cell therapy in patients with progressive systemic sclerosis. Methods Patients with progressive systemic sclerosis received CD19 CAR‐T cell therapy and were followed longitudinally for safety, clinical efficacy, immune ...
Chenhan Jia, Wanyi Lin, Zhangyi Zhao, Fenglin Wu, Chaoyu Gu, Yuankai Sun, Zhe Ding, Chang Wei, Xinyu Li, Cuiwei Xie, Peng Xia, Zhen Xia, Xuesong Liu, Shaoying Yang, Chunyan Zhang, Hanlin Yin, Liangjing Lu   +16 more
wiley   +1 more source

Nerandomilast in Autoimmune-Associated Interstitial Lung Diseases: Translating Evidence from Progressive Pulmonary Fibrosis Studies. [PDF]

J Clin Med
Perrotta F, Mariniello DF, Stella GM, Pagliaro R, Scialò F, Liakouli V, Forte G, Ciccia F, Bianco A, D'Agnano V.   +9 more
europepmc   +1 more source

Expert Perspectives: Defining and managing progressive pulmonary fibrosis in systemic sclerosis

Arthritis &Rheumatology, Accepted Article.
‐‐
Devis Benfaremo, Dinesh Khanna, Corrado Campochiaro, Vincent Cottin, Fabrizio Luppi, Marco Matucci‐Cerinic, Gianluca Moroncini, Yannick Allanore   +7 more
wiley   +1 more source

Remote patient monitoring in autoimmune related interstitial lung diseases: a narrative review. [PDF]

Front Immunol
Althobiani MA, Almoagal M.
europepmc   +1 more source

Human Fibroblast‐Myeloid cell tissue atlas across lung, synovium, skin and heart

Arthritis &Rheumatology, Accepted Article.
Background The availability of single‐cell RNA sequencing (scRNAseq data) in different tissues and disease states provides an opportunity to compare cellular subsets and identify common and unique cellular activation. In this study, we aimed to characterize shared and tissue‐specific myeloid and stromal phenotypes and to uncover key cellular subtypes ...
Lucy MacDonald, Katerina Apostolopoulou, Olympia Hardy, Melpomeni Toitou, Gabriela Kania, Przemyslaw Blyszczuk, Raphael Micheroli, Thomas D Otto, Mariola Kurowska‐Stolarska, Caroline Ospelt   +9 more
wiley   +1 more source

Interstitial Lung Diseases in Israel: Large Variability in Close Geographic Proximity. [PDF]

Diagnostics (Basel)
Hershko T, Freund O, Schneer S, Segel MJ, Wand O, Bar-Shai A, Shitrit D, Levy L, Adir Y, Unterman A.   +9 more
europepmc   +1 more source

Analysis of interstitial lung disease in pharmacovigilance databases: Coding challenges and interpretation biases—An update

British Journal of Clinical Pharmacology, EarlyView.
Aim Clinically, interstitial lung disease (ILD) is a heterogeneous group of respiratory disorders. Due to their low incidence, pharmacovigilance database analysis is useful to detect them. Precise diagnosis is challenging as well as coding in these databases. Query criteria are among the key elements for a good signal detection.
Romane Freppel, Adeline Benis, Philippe Bonniaud, Jean‐Luc Faillie, Aurélie Grandvuillemin   +4 more
wiley   +1 more source